KR20160121602A - 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법 - Google Patents

정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법 Download PDF

Info

Publication number
KR20160121602A
KR20160121602A KR1020167027918A KR20167027918A KR20160121602A KR 20160121602 A KR20160121602 A KR 20160121602A KR 1020167027918 A KR1020167027918 A KR 1020167027918A KR 20167027918 A KR20167027918 A KR 20167027918A KR 20160121602 A KR20160121602 A KR 20160121602A
Authority
KR
South Korea
Prior art keywords
pyrrolo
dihydro
quinolin
trans
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167027918A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 피. 리드
네일 알. 바르네스
존 씨. 케인
크로스토퍼 에이. 리
지안-지에 첸
마르틴 피. 레드몬
Original Assignee
아르퀼 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르퀼 인코포레이티드 filed Critical 아르퀼 인코포레이티드
Publication of KR20160121602A publication Critical patent/KR20160121602A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020167027918A 2009-12-23 2010-12-21 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법 Ceased KR20160121602A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289,563 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127019155A Division KR101669707B1 (ko) 2009-12-23 2010-12-21 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법

Publications (1)

Publication Number Publication Date
KR20160121602A true KR20160121602A (ko) 2016-10-19

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167027918A Ceased KR20160121602A (ko) 2009-12-23 2010-12-21 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법
KR1020127019155A Active KR101669707B1 (ko) 2009-12-23 2010-12-21 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127019155A Active KR101669707B1 (ko) 2009-12-23 2010-12-21 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법

Country Status (19)

Country Link
US (3) US8552192B2 (https=)
EP (2) EP2515904A4 (https=)
JP (2) JP2013515737A (https=)
KR (2) KR20160121602A (https=)
CN (2) CN104910159A (https=)
AU (2) AU2010336533B9 (https=)
BR (1) BR112012015656A2 (https=)
CA (1) CA2785503A1 (https=)
CO (1) CO6561823A2 (https=)
HK (1) HK1215025A1 (https=)
MX (1) MX2012007259A (https=)
MY (2) MY156701A (https=)
NZ (2) NZ600800A (https=)
PH (2) PH12012501293A1 (https=)
RU (1) RU2556205C2 (https=)
SG (1) SG181927A1 (https=)
TW (3) TW201643163A (https=)
WO (1) WO2011079142A2 (https=)
ZA (1) ZA201204759B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486872T1 (de) * 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
PH12012501293A1 (en) * 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
MX2014000253A (es) * 2011-07-07 2014-10-17 Arqule Inc Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
WO2013162714A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
US9688682B2 (en) * 2013-07-16 2017-06-27 Dr. Reddy's Laboratories Limited Crystalline forms of pemetrexed tromethamine salts
EP3665176B1 (en) 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL307471A (en) * 2021-04-07 2023-12-01 Ur 1 Therapeutics Inc URAT1 inhibitor, pharmaceutical preparations and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1527034B1 (en) * 2002-07-31 2006-01-04 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
CA2573508A1 (en) * 2004-09-10 2006-03-23 Wyeth Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyrano[3, 4-b]-indole derivatives
ATE486872T1 (de) * 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
EP2392574B1 (en) * 2007-06-22 2013-12-18 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
PH12012501293A1 (en) * 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2013162714A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Also Published As

Publication number Publication date
US9499540B2 (en) 2016-11-22
CN104910159A (zh) 2015-09-16
KR20120113760A (ko) 2012-10-15
TW201141865A (en) 2011-12-01
WO2011079142A3 (en) 2011-11-24
WO2011079142A2 (en) 2011-06-30
NZ600800A (en) 2014-10-31
US20140031551A1 (en) 2014-01-30
JP2013515737A (ja) 2013-05-09
CO6561823A2 (es) 2012-11-15
EP3081567A2 (en) 2016-10-19
TW201643163A (zh) 2016-12-16
RU2556205C2 (ru) 2015-07-10
PH12012501293A1 (en) 2013-01-07
AU2010336533B9 (en) 2015-10-08
MY169232A (en) 2019-03-19
AU2010336533B2 (en) 2015-09-10
KR101669707B1 (ko) 2016-10-27
EP2515904A4 (en) 2013-07-03
TW201542546A (zh) 2015-11-16
CA2785503A1 (en) 2011-06-30
TWI557125B (zh) 2016-11-11
US20110160242A1 (en) 2011-06-30
US8552192B2 (en) 2013-10-08
CN102834097A (zh) 2012-12-19
US20160024076A1 (en) 2016-01-28
EP3081567A3 (en) 2016-11-16
SG181927A1 (en) 2012-07-30
JP2016041712A (ja) 2016-03-31
RU2012131344A (ru) 2014-01-27
US8871933B2 (en) 2014-10-28
AU2015243015B2 (en) 2017-02-02
TWI506026B (zh) 2015-11-01
NZ628087A (en) 2016-02-26
AU2015243015A1 (en) 2015-11-05
PH12014500310A1 (en) 2015-09-28
MX2012007259A (es) 2015-05-15
AU2010336533A1 (en) 2012-07-12
BR112012015656A2 (pt) 2016-05-10
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
CN102834097B (zh) 2015-06-17
EP2515904A2 (en) 2012-10-31
HK1215025A1 (zh) 2016-08-12

Similar Documents

Publication Publication Date Title
KR101669707B1 (ko) 정제된 피롤로퀴놀리닐-피롤리딘-2,5-디온 조성물 및 이의 제조 방법 및 사용 방법
JP2022140637A (ja) 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩
EP3037424B1 (en) Novel quinoline-substituted compound
JP6268276B2 (ja) ＰＥＲＫ阻害剤としての新規なＮ（２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン−５−イル）−４−キナゾリンアミン誘導体およびＮ−（２，３−ジヒドロ−１Ｈ−インドール−５−イル）−４−キナゾリンアミン誘導体
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
WO2022111644A1 (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
WO2016090257A1 (en) Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
CN113620974A (zh) 大环类酪氨酸激酶抑制剂的晶型及其制备方法
CN104884456B (zh) PI3K和/或mTOR抑制剂
TW201136930A (en) Bridged morpholino substituted purines
CN117794902A (zh) ErbB和BTK抑制剂的新型药用盐和多晶型形式
TWI889173B (zh) 含苯基取代的二氫萘啶類化合物的藥物製劑與用途
CN121846100A (zh) 多靶点喹唑啉酮类衍生物的合成及其在制备缺血性脑卒中药物中的应用
KR20210050530A (ko) 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161007

Application number text: 1020127019155

Filing date: 20120720

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161014

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170117

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170801

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170117

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I